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Background: The ATP7A gene encodes a copper transporter whose mutations cause Menkes disease,
occipital horn syndrome (OHS), and, less frequently, ATP7A-related distal hereditary motor neuropathy
(dHMN). Here we describe a family with OHS caused by a novel mutation in the ATP7A gene, including a
patient with a comorbid dHMN that worsened markedly after being treated with copper histidinate.
Methods: We studied in detail the clinical features of the patients and performed a genomic analysis by
using TruSight One Expanded Sequencing Panel. Subsequently, we determined the ATP7A and ATP7B
expression levels,mitochondrialmembranepotential, and redoxbalance in culturedfibroblasts of Patient 1.
Results: We found a novel ATP7A late truncated mutation p.Lys1412AsnfsX15 in the two affected
members of this family. The co-occurrence of OHS and dHMN in Patient 1 reveals the variable phenotypic
expressivity of the variant. A severe clinical and neurophysiologic worsening was observed in the dHMN
of Patient 1 when he was treated with copper replacement therapy, with a subsequent fast recovery after
the copper histidinate was withdrawn. Functional studies revealed that the patient had low levels of both
ATP7A and ATP7B, the other copper transporter, and high levels of superoxide ion in the mitochondria.n Ramon Areces (grant no. CIVP18A3913), Fundacion Amigos de Nono, Instituto Salud Carlos III Grant DTS16/00196, the
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D. Natera-de Benito, A. Sola, P.R. Sousa et al. Pediatric Neurology 119 (2021) 40e44Conclusions: Our findings broaden the clinical spectrum of ATP7A-related disorders and demonstrate that
two clinical phenotypes can occur in the same patient. The copper-induced toxicity and low levels of
both ATP7A and ATP7B in our patient suggest that copper accumulation in motor neurons is the path-
ogenic mechanism in ATP7A-related dHMN.
© 2021 Elsevier Inc. All rights reserved.Introduction
ATP7A is a transmembrane protein that (1) exports copper
across the plasma membrane to maintain intracellular copper
homeostasis and (2) provides copper to copper-dependent en-
zymes in the trans-Golgi network.1 Mutations in the ATP7A gene
may lead to three distinct X-linked recessive clinical phenotypes:
Menkes disease (MD, MIM #309400), occipital horn syndrome
(OHS, MIM #304150), and ATP7A-related distal hereditary motor
neuropathy (dHMN, MIM #300489). The dHMN phenotype is a
pure motor neuropathy in which, unlike MD and OHS, the
copper-related biochemical parameters are normal.2,3 Although
copper is relevant to maintain the integrity of motor neurons
(MNs), the precise mechanisms by which dysfunctional ATP7A
leads to the specific length-dependent axonal degeneration
observed in MNs of patients with ATP7A-related dHMN remain
unknown.
Here we present a family with OHS due to a novel ATP7A late
truncating variant. In addition to OHS, the older patient has a
dHMN that severely worsened while treated with copper replace-
ment therapy, which may be key to understanding the pathogenic
mechanism in ATP7A-related dHMN.Patient Descriptions
Patient 1 is a 24-year-old male, the maternal uncle of Patient 2.
He had experienced gait difficulties since age three years along
with learning difficulties and symptoms of dysautonomia (syncope
related to orthostatic hypotension and temperature instability).
Physical examination at age 10 years revealed a high forehead, large
ears, pectus excavatum, and normal hair (Fig 1A). Trichoscopy was
not performed. His skin was lax and hyperextensible, and his joints
were hypermobile. Distal muscle weakness in his lower limbs was
detected (tibialis anterior: Medical Research Coucil scale grade 4-/
5). Serum copper levels were 313 mg/L (normal range: 620 to 1544
mg/L) and ceruloplasmin level was 103 mg/L (normal range: 170 to
460 mg/L). Occipital exostoses at the tendinous insertions of the
sternocleidomastoid and trapezius muscles were observed in skull
radiographs (Fig 1F). The brain angio-magnetic resonance imaging
showed that anterior and middle cerebral arteries were elongated
and tortuous (Fig 1B). The first electroneurography test (ENG),
performed when the patient was aged 10 years, showed reduced
amplitude of the compound motor action potentials (CMAPs) with
normal velocity, whereas sensory nerve conductions were normal.
Positive waves and fibrillations were observed via electromyog-
raphy (EMG). All these findings confirmed an axonal neuropathy
predominantly affecting motor nerves (Table). A frameshift variant
ATP7A c.4236delA; p.Lys1412AsnfsX15 that causes a truncated
peptide that preserves all ATP7A domains except the carboxyl ter-
minal (Fig 1G) was detected after genomic DNAwas analyzed using
the TruSight One Expanded Sequencing Panel in a NextSeq 500
platform (Illumina, San Diego, California, USA). The unaffected
mother was heterozygous for the variant. No pathogenic variants
were identified in any of the other known causative genes for
inherited neuropathies.41Patient 2 is a 10-year-old boy, son of Patient 1’s sister. Exami-
nation at age 10 months showed global hypotonia, down-slanting
eyes, internal epicanthus, prominent large ears, hypermobile
joints, lax skin, and hair that was hypopigmented, dull, and friable
(Fig 1D). Pili torti was observed through optic microscopy (Fig 1C).
Mild motor delay was detected. Serum copper and ceruloplasmin
were in the normal range (1123 mg/L [normal range: 620 to 1544
mg/L] and 225 mg/L [normal range: 220 to 470 mg/L], respectively).
Vascular tortuosity and dilatation of the Willis polygon and basilar
and vertebral arteries were observed in a cerebral magnetic
resonance imaging (Fig 1E). His ENG/EMG evaluation was normal,
with peroneal CMAP and nerve conduction velocity within the
normal range (2.6 mV and 55.4 m/s, respectively). It is not known
if Patient 2 had occipital exostoses because a skull x-ray was not
performed.
Because some patients with MD had proven to be responsive to
early copper replacement therapy4,5 and since copper supple-
mentation may be potentially beneficial in OHS,6 we treated Pa-
tient 1 with copper histidinate at age 15 years, after having
obtained an informed consent from the family. Doses of 20 mg/kg
were administered three times per week and increased to four
times per week after serum levels of copper and ceruloplasmin
were tested. The treatment was withdrawn after four months due
to a marked worsening of the motor symptoms, with increased
distal muscular weakness in all four limbs. His gait worsened
considerably, and significant difficulties to perform daily activities
appeared. Actions such as pulling out a book from his bag, writing,
or picking up a glass of water became very difficult for him, if not
impossible. The ENG/EMG evaluation was repeated after four
months of treatment, and it demonstrated a lower CMAP and clear
signs of denervation (Table). Once the copper histidinate treat-
ment was withdrawn, the adverse side effects disappeared pro-
gressively and rapidly until the functional status of the patient was
completely recovered. Four months after the copper was with-
drawn, the neurophysiologic evaluation showed similar results to
those obtained in the ENG/EMG performed before the start of
treatment (Table).Functional studies
Because ATP7A and ATP7B are two copper transporters that act
in a coordinated manner in neurons,7 we quantified their levels in
fibroblasts of Patient 1 and compared them with the levels in fi-
broblasts of two patients with the main inborn errors of copper
metabolism: MD and Wilson disease (WD), as well as the levels in
fibroblasts of control individuals (Fig 2A and B). ATP7A showed
small size and was poorly expressed in Patient 1 fibroblasts, absent
in MD fibroblasts, and normal in controls and WD fibroblasts.
Intriguingly, ATP7B was also significantly lower in Patient 1 than in
the other individuals. Exome re-analysis of the ATP7B gene did not
detect any pathogenic variants in Patient 1, which suggests that this
lower level of ATP7B could be related to the low expression of
ATP7ALys1412AsnfsX15.
As ATP7A is essential for redox balance in mitochondria, we
quantified the levels of mitochondria superoxide (MitoSOX Red
FIGURE 1. (A) Frontal view of Patient 1 at age 16 years. Note the large ears and lax and hyperextensible skin. (B, E) Vascular tortuosity and dilatation of the Willis polygon and basilar
and vertebral arteries were observed in the cerebral angio-magnetic resonance imaging of both Patient 1 (B) and Patient 2 (E). (C) Pili torti of Patient 2 was revealed through optical
microcopy. (D) Frontal view of Patient 2 at age three years. Note down-slanting eyes, internal epicanthus, prominent large ears, and hypopigmented, dull, and friable hair. (F) Typical
occipital exostoses at the tendinous insertions of the sternocleidomastoid and trapezius muscles were observed in lateral skull radiograph of Patient 1. (G) ATP7A structure
(NP_000043.4). Note the location of the novel p.Lys1412AsnfsX15 mutation, as well as those previously reported missense mutations in patients with CMT phenotype (black dots).
TM, transmembrane domains; Ph-tase, phosphatase domain; Ph-ryl, phosphorylation domain. The color version of this figure is available in the online edition.
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thylrhodamine methyl ester perchlorate, Sigma-Aldrich) in pa-
tients’ fibroblasts using flow cytometry. We observed high levels of
superoxide ion in the mitochondria of all patients’ fibroblasts (Fig
2C). In contrast, membrane potential was only affected in MD fi-
broblasts (Fig 2D). Further characterization of fibroblasts’ redox
status using glutathione quantification revealed normal levels of
both reduced glutathione (GSH) and oxidized glutathione (GSSG)
(GSH/GSSG-Glo Assay, Promega) in fibroblasts of Patient 1 and the
patient with WD, whereas the patient with MD showed signifi-
cantly higher levels of GSSG (Fig 2E and F). Collectively, these data
showed important differences in both the correlation of ATP7A/
ATP7B expression and in oxidative status across patients with OHS,
MD, and WD.
Discussion
Here we describe two related patients with OHS, one of them
with comorbid dHMN. Both patients carry the frameshift mutation42p.Lys1412AsnfsX15 in ATP7A, which affects the last intra-
cytoplasmic ATP7A domain. Unlike other truncating ATP7A variants,
which cause MD, late truncating variants located at the C-t lead to
an OHS phenotype by removing the distal di-leucine motif
L1477L1478.8 The lack of this motif, which is an endocytic signal for
ATP7A recycling between the trans-Golgi network and the plasma
membrane, leads to a truncated ATP7A predominantly located at
the plasma membrane.9 The resulting ATP7Ap.Lys1412AsnfsX15
shortage at the trans-Golgi network would limit the copper supply
to the copper-dependent enzymes lysyl oxidase and dopamine-
ß-hydroxylase, eventually leading to the typical signs of OHS. The
finding of pili torti in Patient 2, with normal serum copper and
ceruloplasmin, would also be explained by the intracellular
mislocation of ATP7A. Pili torti structure is caused by malformation
of keratin due to lack of sulfhydryl oxidase.10 Sulfhydryl oxidase
typically functions in the endoplasmic reticulum, catalyzed by
copper, to promote disulfide bond-forming reactions, which are
necessary for keratin cross-linking. The prevalence of pili torti in
patients with OHS is still unknown. On the other hand, normal
FIGURE 2. Functional studies of mitochondria and oxidative stress parameters in fibroblast. (A, B) Western blot and quantification of ATP7A (A) and ATP7B (B) in fibroblast. (C, D)
Quantification of MitoSOX (MTSX) and TMRM staining to detect mitochondrial superoxide and mitochondrial membrane potential, respectively. (E) Reduced (GSH) and (F) oxidized
(GSSG) glutathione (nmol/mg protein). Data are means þ SEM from 6 independent experiments related to three control samples. *P < 0.05, **P < 0.01, ***P < 0.001. MD, Menkes
disease (ATP7A genotype: p.Arg980fs); WD, Wilson disease (ATP7B genotype: p.Met645Arg/p.His1069Glu); OHS, occipital horn syndrome (ATP7A genotype: p.Lys1412AsnfsX15).
TABLE.
Patient 1 Neurophysiologic Examinations
Biochemical and Neurophysiological
Parameters
Before Cu Therapy (Basal
Values)
During Cu Therapy (4 Months on
Treatment)
After Cu Therapy (4 Months Without
Treatment)
Copper serum levels (mg/L)
Normal range (620-1544 mg/L) 313 604 359
Nerve conduction study
R peroneal nerve CMAP (mV) 0.6 0.3 0.6
R peroneal NCV (m/s) 47.3 35.8 34.5
L suralis SNAP (mV) 9.1 6.2 2.2
L suralis sensory NCV (m/s) 56.7 48.2 62.5
EMG study
Fibrillations 2/10 2/10 NP
Positive waves 2/10 2/10 NP
Amplitude þþ þþ NP
Duration þþ þþþ NP
Firing - – NP
Abbreviations:
CMAP ¼ Compound motor action potential
Cu ¼ Copper
L ¼ Left
NCV ¼ Nerve conduction velocity
NP ¼ Not performed
R ¼ Right
SNAP ¼ Sensory nerve action potential
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29% and 26% of patients with OHS, respectively.11 This variability
could be due to differences in the reduced amount of ATP7A vari-
ants and in their location, which could prevent the reduction of
these biomarkers in some patients, in contrast to what is observed
in the total absence of ATP7A in Menkes disease. In our family, the
differences in copper management between Patients 1 and 2,
although they are uncles and nephews, may be related to individual
genomic background.
The three missense variants in transmembrane domains that
have been previously documented in patients with ATP7A-related
dHMN also results in a preferential location of ATP7A at the
plasma membrane.12 Therefore the accumulation of ATP7A at the
plasma membrane seems a common pathophysiologic mecha-
nism to explain the unique association of OHS and dHMN
observed in Patient 1. Moreover, one of the previously reported
dHMN-causing variants (ATP7APro1386Ser) has been associated
with reduced calcium (Ca2þ) removal and synapses recovery in
NSC-34 cells.13 Since mitochondria contribute to Ca2þ buffering
and energy production at synapses,14 it could be hypothesized
that ATP7A-related dHMN variants impair mitochondrial trans-
port, similar to what occurs in MFN2-related Charcot-Marie-
Tooth disease.15 Putative mislocation of ATP7A at the plasma
membrane would cause a decrease in the number of mitochon-
dria at synapses, leading to synaptic dysfunction and neuropathy.
Our comparison of the mitochondrial and cellular oxidative state
in patients with MD and OHS supports the idea that impaired
mitochondrial mobility, and not oxidative stress, would be the
cause of dHMN in Patient 1.
Last, the finding of markedworsening of neuropathy in Patient 1
after copper supplementation could be also explained by the
impaired trafficking of ATP7A, which would be unable to properly
remove the excess of copper16,17 and would eventually lead to a
copper accumulation in MNs and axons, which is a known patho-
genic mechanism in neurodegenerative disorders. Patient 1, who
carries the p.Lys1412AsnfsX15 variant in ATP7A and has low levels
of the other copper transporter ATP7B, would have a copper ho-
meostasis defect in MNs that would have eventually resulted in
both dHMN and toxicity after copper supplementation. In neurons,
ATP7B is found in vesicles distributed throughout the cytosol where
it sequesters copper and regulates the amount of cytosolic copper
available for ATP7A.7 Further studies of the ATP7A/ATP7B ratio in
additional patients’ samples are necessary to better understand the
biology of the functional relationship of these copper transporters.
In any case, we propose that Patient 1 has a global defect in the
regulation of intracellular copper levels that causes this particular
OHS phenotype and eventually leads to axonal neuropathy that is44highly susceptible to copper-induced toxicity. In contrast, we found
in MD a total absence of ATP7A and normal levels of ATP7B. These
differences in ATP7A/ATP7B ratio in MD and OHS could explainwhy
copper replacement therapy may be beneficial in patients with MD
and be toxic in patients with OHS. Therefore copper replacement
therapy should be considered and monitored with caution in pa-
tients with dHMN and/or OHS according to the distinct patho-
physiologic mechanisms discussed here.
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